No Prescription |
 |
 | ||
|
Prescription Drugs 1 |
|
| ||
No Prescription » Prescription Drugs 1
Acnecinamide Cleansing Gel Generic NIACINAMIDE Acnecinamide Gel Cream Generic NIACINAMIDE Acnecinamide PHA 10 Gel Generic NIACINAMIDE Activelle Generic Estradiol Norethindrone Actonel Generic Risedronate Sodium Acular Generic Ketorolac Tromethamine Optha Soln Acular LS Generic Ketorolac Tromethamine OpthSoln Acyclovir Cream Generic Zovirax Advantan Cream Generic Methylprednisolone aceponate Advantan Lotion Generic Methylprednisolone aceponate Advantan Ointment Generic Methylprednisolone aceponate Alanase Nasal Spray Generic Beclomethasone Dipropionate Aldactazide Generic Spironolactone Hydrochlorothiazide ALDACTONE Generic Spironolactone Aldara Cream Generic Imiquimod Aldara Generic Imiquimod Cream Alphagan Generic Brimonidine Tartrate ALPHAGAN P Generic Brimonidine Tartrate Alphagan Z Generic Brimonidine Tartrate Ophthalmic solution ALUPENT Generic Orciprenaline Sulphate Anafranil Generic Clomipramine ANGISED Generic Glyceryl Trinitrate
No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
|
|
|